4/1
09:07 am
qure
uniQure (NASDAQ: QURE) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $38.00 price target on the stock.
Medium
Report
uniQure (NASDAQ: QURE) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $38.00 price target on the stock.
3/11
11:07 pm
qure
uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.
3/4
12:27 pm
qure
uniQure (NASDAQ: QURE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Medium
Report
uniQure (NASDAQ: QURE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
2/28
12:49 pm
qure
uniQure (NASDAQ: QURE) had its price target lowered by analysts at Wells Fargo & Company from $35.00 to $30.00. They now have an "equal weight" rating on the stock.
Medium
Report
uniQure (NASDAQ: QURE) had its price target lowered by analysts at Wells Fargo & Company from $35.00 to $30.00. They now have an "equal weight" rating on the stock.
2/27
07:05 am
qure
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
High
Report
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
2/7
09:12 am
qure
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
Medium
Report
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
2/6
12:35 am
qure
uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.
2/3
07:05 am
qure
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
High
Report
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
1/30
07:37 am
qure
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
Medium
Report
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
1/27
08:02 am
qure
uniQure (NASDAQ: QURE) had its price target raised by analysts at HC Wainwright from $25.00 to $70.00. They now have a "buy" rating on the stock.
Low
Report
uniQure (NASDAQ: QURE) had its price target raised by analysts at HC Wainwright from $25.00 to $70.00. They now have a "buy" rating on the stock.
1/21
12:46 pm
qure
uniQure (NASDAQ: QURE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $24.00 price target on the stock.
Low
Report
uniQure (NASDAQ: QURE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $24.00 price target on the stock.
1/8
07:05 am
qure
uniQure Announces Pricing of its Public Offering
Medium
Report
uniQure Announces Pricing of its Public Offering
1/7
04:49 pm
qure
uniQure Announces Proposed Public Offering
Medium
Report
uniQure Announces Proposed Public Offering